We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca has announced that its joint HER2-targeting antibody drug conjugate (ADC) with Daiichi Sankyo has met its primary endpoint in a phase II trial.